



ZIOPHARM Oncology, Inc.  
Investor Relations Department  
One First Ave., Parris Building, # 34  
Navy Yard Plaza  
Boston, MA 02199  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: ZIOP

Last Trade:	6.10
Trade Time:	4:00 PM ET Jul 20, 2017
Change:	0.17 (+2.867%)
Day Range	5.90 - 6.18
52-Week Range	4.45 - 7.88
Volume	1,028,502


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 28, 2017*

[ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma](#)

*Jun 5, 2017*

[ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting](#)

*Jun 2, 2017*

[ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference](#)

*May 17, 2017*

[ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting](#)

*May 12, 2017*

[ZIOPHARM Oncology Announces Pricing of \\$50 Million Follow-On Offering of Common Stock](#)

## Financials [\[ View all \]](#)

*Feb 16, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 1, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 9, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 9, 2016*

[Quarterly Report \(10-Q\)](#)